Xeris Biopharma Holdings received a notice of allowance from the U.S. Patent and Trademark Office for a patent application covering compositions and methods of use for its Keveyis product. The allowed claims are expected to advance toward issuance, and Xeris plans to list the patent in the FDA's Orange Book, potentially extending intellectual property protection for Keveyis through 2039. Separately, Xeris entered exchange agreements to retire approximately $23 million of its 8.00% Convertible Senior Notes due 2028 using cash and common stock, leaving about $10.5 million outstanding after the transaction.
Xeris Pharmaceuticals IncPatent allowance extends Keveyis exclusivity to 2039
Celldex Therapeutics Inc